Benchmark Updates Covidien (COV) Model Following Accounting Changes, Given Imaging Purchase
Tweet Send to a Friend
Benchmark maintains its Buy rating and $82 price target of Covidien (NYSE: COV) following the company's recent change to revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
